It has also been demonstrated that therapeutic blood levels of the drug have been delivered. Additional clinical study protocols are being prepared with a goal of beginning the trials in Q3-Q4 1998. The next step will be a study to evaluate the best site or sites on the body for applying the product. Helicore - Helicore is an experimental product for eradication of H. pylori , an intestinal bacterium responsible for most cases of peptic ulcer disease. H. pylori is also implicated as a causative agent of certain stomach cancers.
Work is ongoing to evaluate other possible formations.
Novavax's Biologics Division develops surface-active lipid structures that have biological activity designed to either inactivate viruses or kill bacteria and spores on contact. The products utilizing these technologies range from oral drugs to vaccine adjuvants and anti-infectives. They illustrate the breath and versatility of the Division's technology and the future potential growth in this area. The Cantab program is utilizing Novavax technology as a potential adjuvant in an immunotherapeutic vaccine for treating cervical dysplasia, a precancerous growth caused by human papilloma virus, which if left untreated can lead to cervical cancer. One percent of the world's 2.9 billion females develops cervical dysplasia.